Bagsværd, Denmark, 8 December 2020 – Novo Nordisk today announced that the acquisition of Emisphere Technologies Inc. (Emisphere), announced on 6 November 2020, has now been completed. The adoption of the merger agreement was approved by Emisphere shareholders today, and early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 was granted on 23 November 2020.
About the acquisition
For more information, please see:
Novo Nordisk to acquire Emisphere Technologies and obtain ownership of the Eligen® SNAC oral delivery technology
About Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 44,000 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.
|Mette Kruse Danielsen||+45 30 79 38 email@example.com|
|Ken Inchausti (US)||+1 609 240 firstname.lastname@example.org|
|Daniel Muusmann Bohsen||+45 3075 email@example.com|
|Valdemar Borum Svarrer||+45 3079 firstname.lastname@example.org|
|Ann Søndermølle Rendbæk||+45 3075 email@example.com|
|Mark Joseph Root||+45 3079 firstname.lastname@example.org|
|Kristoffer Due Berg (US)||+1 609 235 email@example.com|